

Pulmonary Arterial Hypertension (PAH) Drugs Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/P004FDE1CB5BEN.html>

Date: March 2022

Pages: 111

Price: US\$ 3,250.00 (Single User License)

ID: P004FDE1CB5BEN

Abstracts

This report contains market size and forecasts of Pulmonary Arterial Hypertension (PAH) Drugs in global, including the following market information:

Global Pulmonary Arterial Hypertension (PAH) Drugs Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global Pulmonary Arterial Hypertension (PAH) Drugs Market Sales, 2017-2022, 2023-2028, (K Pcs)

Global top five Pulmonary Arterial Hypertension (PAH) Drugs companies in 2021 (%)

The global Pulmonary Arterial Hypertension (PAH) Drugs market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Inhalation Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Pulmonary Arterial Hypertension (PAH) Drugs include Pfizer, Glaxosmithkline, Novartis, United Therapeutics, AstraZeneca, Merck, Bayer Healthcare, Actelion Pharmaceuticals and Daiichi Sankyo, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Pulmonary Arterial

Hypertension (PAH) Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Pulmonary Arterial Hypertension (PAH) Drugs Market, by Type, 2017-2022, 2023-2028 (\$ Millions) & (K Pcs)

Global Pulmonary Arterial Hypertension (PAH) Drugs Market Segment Percentages, by Type, 2021 (%)

Inhalation

Injectables

Oral Administration

Global Pulmonary Arterial Hypertension (PAH) Drugs Market, by Application, 2017-2022, 2023-2028 (\$ Millions) & (K Pcs)

Global Pulmonary Arterial Hypertension (PAH) Drugs Market Segment Percentages, by Application, 2021 (%)

Hospitals

Clinics

Other

Global Pulmonary Arterial Hypertension (PAH) Drugs Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions) & (K Pcs)

Global Pulmonary Arterial Hypertension (PAH) Drugs Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Pulmonary Arterial Hypertension (PAH) Drugs revenues in global market, 2017-2022 (Estimated), (\$ millions)

Key companies Pulmonary Arterial Hypertension (PAH) Drugs revenues share in global market, 2021 (%)

Key companies Pulmonary Arterial Hypertension (PAH) Drugs sales in global market, 2017-2022 (Estimated), (K Pcs)

Key companies Pulmonary Arterial Hypertension (PAH) Drugs sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Pfizer

Glaxosmithkline

Novartis

United Therapeutics

AstraZeneca

Merck

Bayer Healthcare

Actelion Pharmaceuticals

Daiichi Sankyo

Northern Therapeutics

Aires Pharmaceuticals

Arena Pharmaceuticals

Berlin Cures

Eiger BioPharmaceuticals

Reata Pharmaceuticals

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Pulmonary Arterial Hypertension (PAH) Drugs Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS OVERALL MARKET SIZE

- 2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size: 2021 VS 2028
- 2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, Prospects & Forecasts: 2017-2028
- 2.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales: 2017-2028

3 COMPANY LANDSCAPE

- 3.1 Top Pulmonary Arterial Hypertension (PAH) Drugs Players in Global Market
- 3.2 Top Global Pulmonary Arterial Hypertension (PAH) Drugs Companies Ranked by Revenue
- 3.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Companies
- 3.4 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Companies
- 3.5 Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Manufacturer (2017-2022)
- 3.6 Top 3 and Top 5 Pulmonary Arterial Hypertension (PAH) Drugs Companies in Global Market, by Revenue in 2021
- 3.7 Global Manufacturers Pulmonary Arterial Hypertension (PAH) Drugs Product Type
- 3.8 Tier 1, Tier 2 and Tier 3 Pulmonary Arterial Hypertension (PAH) Drugs Players in Global Market
 - 3.8.1 List of Global Tier 1 Pulmonary Arterial Hypertension (PAH) Drugs Companies

3.8.2 List of Global Tier 2 and Tier 3 Pulmonary Arterial Hypertension (PAH) Drugs Companies

4 SIGHTS BY PRODUCT

4.1 Overview

4.1.1 By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Markets, 2021 & 2028

4.1.2 Inhalation

4.1.3 Injectables

4.1.4 Oral Administration

4.2 By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue & Forecasts

4.2.1 By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2017-2022

4.2.2 By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2023-2028

4.2.3 By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2017-2028

4.3 By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales & Forecasts

4.3.1 By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2017-2022

4.3.2 By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2023-2028

4.3.3 By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2017-2028

4.4 By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Price (Manufacturers Selling Prices), 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2021 & 2028

5.1.2 Hospitals

5.1.3 Clinics

5.1.4 Other

5.2 By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue & Forecasts

5.2.1 By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2017-2022

5.2.2 By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2023-2028

5.2.3 By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2017-2028

5.3 By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales & Forecasts

5.3.1 By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2017-2022

5.3.2 By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2023-2028

5.3.3 By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2017-2028

5.4 By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Price (Manufacturers Selling Prices), 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2021 & 2028

6.2 By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue & Forecasts

6.2.1 By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2017-2022

6.2.2 By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2023-2028

6.2.3 By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2017-2028

6.3 By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales & Forecasts

6.3.1 By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2017-2022

6.3.2 By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2023-2028

6.3.3 By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2017-2028

6.4 North America

6.4.1 By Country - North America Pulmonary Arterial Hypertension (PAH) Drugs

Revenue, 2017-2028

6.4.2 By Country - North America Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2017-2028

6.4.3 US Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028

6.4.4 Canada Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028

6.4.5 Mexico Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028

6.5 Europe

6.5.1 By Country - Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2017-2028

6.5.2 By Country - Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2017-2028

6.5.3 Germany Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028

6.5.4 France Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028

6.5.5 U.K. Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028

6.5.6 Italy Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028

6.5.7 Russia Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028

6.5.8 Nordic Countries Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028

6.5.9 Benelux Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028

6.6 Asia

6.6.1 By Region - Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2017-2028

6.6.2 By Region - Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2017-2028

6.6.3 China Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028

6.6.4 Japan Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028

6.6.5 South Korea Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028

6.6.6 Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028

6.6.7 India Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028

6.7 South America

6.7.1 By Country - South America Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2017-2028

6.7.2 By Country - South America Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2017-2028

6.7.3 Brazil Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028

6.7.4 Argentina Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028

6.8 Middle East & Africa

6.8.1 By Country - Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2017-2028

6.8.2 By Country - Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2017-2028

6.8.3 Turkey Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028

6.8.4 Israel Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028

6.8.5 Saudi Arabia Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028

6.8.6 UAE Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028

7 MANUFACTURERS & BRANDS PROFILES

7.1 Pfizer

7.1.1 Pfizer Corporate Summary

7.1.2 Pfizer Business Overview

7.1.3 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings

7.1.4 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2017-2022)

7.1.5 Pfizer Key News

7.2 Glaxosmithkline

7.2.1 Glaxosmithkline Corporate Summary

7.2.2 Glaxosmithkline Business Overview

7.2.3 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings

7.2.4 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2017-2022)

7.2.5 Glaxosmithkline Key News

7.3 Novartis

7.3.1 Novartis Corporate Summary

7.3.2 Novartis Business Overview

7.3.3 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings

7.3.4 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2017-2022)

7.3.5 Novartis Key News

7.4 United Therapeutics

7.4.1 United Therapeutics Corporate Summary

7.4.2 United Therapeutics Business Overview

7.4.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings

7.4.4 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2017-2022)

7.4.5 United Therapeutics Key News

7.5 AstraZeneca

7.5.1 AstraZeneca Corporate Summary

7.5.2 AstraZeneca Business Overview

7.5.3 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings

7.5.4 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2017-2022)

7.5.5 AstraZeneca Key News

7.6 Merck

7.6.1 Merck Corporate Summary

7.6.2 Merck Business Overview

7.6.3 Merck Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings

7.6.4 Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2017-2022)

7.6.5 Merck Key News

7.7 Bayer Healthcare

7.7.1 Bayer Healthcare Corporate Summary

7.7.2 Bayer Healthcare Business Overview

7.7.3 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings

7.7.4 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2017-2022)

7.7.5 Bayer Healthcare Key News

7.8 Actelion Pharmaceuticals

7.8.1 Actelion Pharmaceuticals Corporate Summary

7.8.2 Actelion Pharmaceuticals Business Overview

7.8.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings

7.8.4 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2017-2022)

7.8.5 Actelion Pharmaceuticals Key News

7.9 Daiichi Sankyo

7.9.1 Daiichi Sankyo Corporate Summary

7.9.2 Daiichi Sankyo Business Overview

7.9.3 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings

7.9.4 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2017-2022)

7.9.5 Daiichi Sankyo Key News

7.10 Northern Therapeutics

7.10.1 Northern Therapeutics Corporate Summary

7.10.2 Northern Therapeutics Business Overview

7.10.3 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings

7.10.4 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2017-2022)

7.10.5 Northern Therapeutics Key News

7.11 Aires Pharmaceuticals

7.11.1 Aires Pharmaceuticals Corporate Summary

7.11.2 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Business Overview

7.11.3 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings

7.11.4 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2017-2022)

7.11.5 Aires Pharmaceuticals Key News

7.12 Arena Pharmaceuticals

7.12.1 Arena Pharmaceuticals Corporate Summary

7.12.2 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Business Overview

7.12.3 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings

7.12.4 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2017-2022)

7.12.5 Arena Pharmaceuticals Key News

7.13 Berlin Cures

7.13.1 Berlin Cures Corporate Summary

7.13.2 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Business Overview

7.13.3 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings

7.13.4 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2017-2022)

7.13.5 Berlin Cures Key News

7.14 Eiger BioPharmaceuticals

7.14.1 Eiger BioPharmaceuticals Corporate Summary

- 7.14.2 Eiger BioPharmaceuticals Business Overview
- 7.14.3 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings
- 7.14.4 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2017-2022)
- 7.14.5 Eiger BioPharmaceuticals Key News
- 7.15 Reata Pharmaceuticals
 - 7.15.1 Reata Pharmaceuticals Corporate Summary
 - 7.15.2 Reata Pharmaceuticals Business Overview
 - 7.15.3 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings
 - 7.15.4 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2017-2022)
 - 7.15.5 Reata Pharmaceuticals Key News

8 GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS PRODUCTION CAPACITY, ANALYSIS

- 8.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity, 2017-2028
- 8.2 Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity of Key Manufacturers in Global Market
- 8.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Production by Region

9 KEY MARKET TRENDS, OPPORTUNITY, DRIVERS AND RESTRAINTS

- 9.1 Market Opportunities & Trends
- 9.2 Market Drivers
- 9.3 Market Restraints

10 PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS SUPPLY CHAIN ANALYSIS

- 10.1 Pulmonary Arterial Hypertension (PAH) Drugs Industry Value Chain
- 10.2 Pulmonary Arterial Hypertension (PAH) Drugs Upstream Market
- 10.3 Pulmonary Arterial Hypertension (PAH) Drugs Downstream and Clients
- 10.4 Marketing Channels Analysis
 - 10.4.1 Marketing Channels
 - 10.4.2 Pulmonary Arterial Hypertension (PAH) Drugs Distributors and Sales Agents in

Global

11 CONCLUSION

12 APPENDIX

12.1 Note

12.2 Examples of Clients

12.3 Disclaimer

List Of Tables

LIST OF TABLES

- Table 1. Key Players of Pulmonary Arterial Hypertension (PAH) Drugs in Global Market
- Table 2. Top Pulmonary Arterial Hypertension (PAH) Drugs Players in Global Market, Ranking by Revenue (2021)
- Table 3. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Companies, (US\$, Mn), 2017-2022
- Table 4. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Companies, 2017-2022
- Table 5. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Companies, (K Pcs), 2017-2022
- Table 6. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Companies, 2017-2022
- Table 7. Key Manufacturers Pulmonary Arterial Hypertension (PAH) Drugs Price (2017-2022) & (USD/Pcs)
- Table 8. Global Manufacturers Pulmonary Arterial Hypertension (PAH) Drugs Product Type
- Table 9. List of Global Tier 1 Pulmonary Arterial Hypertension (PAH) Drugs Companies, Revenue (US\$, Mn) in 2021 and Market Share
- Table 10. List of Global Tier 2 and Tier 3 Pulmonary Arterial Hypertension (PAH) Drugs Companies, Revenue (US\$, Mn) in 2021 and Market Share
- Table 11. By Type – Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn), 2021 & 2028
- Table 12. By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US\$, Mn), 2017-2022
- Table 13. By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US\$, Mn), 2023-2028
- Table 14. By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), 2017-2022
- Table 15. By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), 2023-2028
- Table 16. By Application – Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn), 2021 & 2028
- Table 17. By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US\$, Mn), 2017-2022
- Table 18. By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US\$, Mn), 2023-2028

Table 19. By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), 2017-2022

Table 20. By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), 2023-2028

Table 21. By Region – Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn), 2021 VS 2028

Table 22. By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US\$, Mn), 2017-2022

Table 23. By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US\$, Mn), 2023-2028

Table 24. By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), 2017-2022

Table 25. By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), 2023-2028

Table 26. By Country - North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - North America Pulmonary Arterial Hypertension (PAH) Drugs Sales, (K Pcs), 2017-2022

Table 29. By Country - North America Pulmonary Arterial Hypertension (PAH) Drugs Sales, (K Pcs), 2023-2028

Table 30. By Country - Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn), 2017-2022

Table 31. By Country - Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn), 2023-2028

Table 32. By Country - Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales, (K Pcs), 2017-2022

Table 33. By Country - Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales, (K Pcs), 2023-2028

Table 34. By Region - Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn), 2017-2022

Table 35. By Region - Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn), 2023-2028

Table 36. By Region - Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales, (K Pcs), 2017-2022

Table 37. By Region - Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales, (K Pcs), 2023-2028

Table 38. By Country - South America Pulmonary Arterial Hypertension (PAH) Drugs

Revenue, (US\$, Mn), 2017-2022

Table 39. By Country - South America Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn), 2023-2028

Table 40. By Country - South America Pulmonary Arterial Hypertension (PAH) Drugs Sales, (K Pcs), 2017-2022

Table 41. By Country - South America Pulmonary Arterial Hypertension (PAH) Drugs Sales, (K Pcs), 2023-2028

Table 42. By Country - Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn), 2017-2022

Table 43. By Country - Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn), 2023-2028

Table 44. By Country - Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales, (K Pcs), 2017-2022

Table 45. By Country - Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales, (K Pcs), 2023-2028

Table 46. Pfizer Corporate Summary

Table 47. Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings

Table 48. Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 49. Glaxosmithkline Corporate Summary

Table 50. Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings

Table 51. Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 52. Novartis Corporate Summary

Table 53. Novartis Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings

Table 54. Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 55. United Therapeutics Corporate Summary

Table 56. United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings

Table 57. United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 58. AstraZeneca Corporate Summary

Table 59. AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings

Table 60. AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 61. Merck Corporate Summary

Table 62. Merck Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings

Table 63. Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 64. Bayer Healthcare Corporate Summary

Table 65. Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings

Table 66. Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 67. Actelion Pharmaceuticals Corporate Summary

Table 68. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings

Table 69. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 70. Daiichi Sankyo Corporate Summary

Table 71. Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings

Table 72. Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 73. Northern Therapeutics Corporate Summary

Table 74. Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings

Table 75. Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 76. Aires Pharmaceuticals Corporate Summary

Table 77. Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings

Table 78. Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 79. Arena Pharmaceuticals Corporate Summary

Table 80. Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings

Table 81. Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 82. Berlin Cures Corporate Summary

Table 83. Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings

Table 84. Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 85. Eiger BioPharmaceuticals Corporate Summary

Table 86. Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings

Table 87. Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 88. Reata Pharmaceuticals Corporate Summary

Table 89. Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings

Table 90. Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 91. Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity (K Pcs) of Key Manufacturers in Global Market, 2020-2022 (K Pcs)

Table 92. Global Pulmonary Arterial Hypertension (PAH) Drugs Capacity Market Share of Key Manufacturers, 2020-2022

Table 93. Global Pulmonary Arterial Hypertension (PAH) Drugs Production by Region, 2017-2022 (K Pcs)

Table 94. Global Pulmonary Arterial Hypertension (PAH) Drugs Production by Region, 2023-2028 (K Pcs)

Table 95. Pulmonary Arterial Hypertension (PAH) Drugs Market Opportunities & Trends in Global Market

Table 96. Pulmonary Arterial Hypertension (PAH) Drugs Market Drivers in Global Market

Table 97. Pulmonary Arterial Hypertension (PAH) Drugs Market Restraints in Global Market

Table 98. Pulmonary Arterial Hypertension (PAH) Drugs Raw Materials

Table 99. Pulmonary Arterial Hypertension (PAH) Drugs Raw Materials Suppliers in Global Market

Table 100. Typical Pulmonary Arterial Hypertension (PAH) Drugs Downstream

Table 101. Pulmonary Arterial Hypertension (PAH) Drugs Downstream Clients in Global Market

Table 102. Pulmonary Arterial Hypertension (PAH) Drugs Distributors and Sales Agents in Global Market

List Of Figures

LIST OF FIGURES

Figure 1. Pulmonary Arterial Hypertension (PAH) Drugs Segment by Type

Figure 2. Pulmonary Arterial Hypertension (PAH) Drugs Segment by Application

Figure 3. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Overview: 2021

Figure 4. Key Caveats

Figure 5. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size: 2021 VS 2028 (US\$, Mn)

Figure 6. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2017-2028 (US\$, Mn)

Figure 7. Pulmonary Arterial Hypertension (PAH) Drugs Sales in Global Market: 2017-2028 (K Pcs)

Figure 8. The Top 3 and 5 Players Market Share by Pulmonary Arterial Hypertension (PAH) Drugs Revenue in 2021

Figure 9. By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2017-2028

Figure 10. By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2017-2028

Figure 11. By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Price (USD/Pcs), 2017-2028

Figure 12. By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2017-2028

Figure 13. By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2017-2028

Figure 14. By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Price (USD/Pcs), 2017-2028

Figure 15. By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2017-2028

Figure 16. By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2017-2028

Figure 17. By Country - North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2017-2028

Figure 18. By Country - North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2017-2028

Figure 19. US Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 20. Canada Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn),

2017-2028

Figure 21. Mexico Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 22. By Country - Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2017-2028

Figure 23. By Country - Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2017-2028

Figure 24. Germany Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 25. France Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 26. U.K. Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 27. Italy Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 28. Russia Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 29. Nordic Countries Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 30. Benelux Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 31. By Region - Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2017-2028

Figure 32. By Region - Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2017-2028

Figure 33. China Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 34. Japan Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 35. South Korea Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 36. Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 37. India Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 38. By Country - South America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2017-2028

Figure 39. By Country - South America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2017-2028

Figure 40. Brazil Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 41. Argentina Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 42. By Country - Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2017-2028

Figure 43. By Country - Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2017-2028

Figure 44. Turkey Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 45. Israel Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 46. Saudi Arabia Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 47. UAE Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US\$, Mn), 2017-2028

Figure 48. Global Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity (K Pcs), 2017-2028

Figure 49. The Percentage of Production Pulmonary Arterial Hypertension (PAH) Drugs by Region, 2021 VS 2028

Figure 50. Pulmonary Arterial Hypertension (PAH) Drugs Industry Value Chain

Figure 51. Marketing Channels

I would like to order

Product name: Pulmonary Arterial Hypertension (PAH) Drugs Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/P004FDE1CB5BEN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P004FDE1CB5BEN.html>